Shots:

• The approval is based on P-III IKEMA study involves assessing of Sarclisa + carfilzomib and dexamethasone(kd) vs SOC in 302 patients with RRMM who had received 1 to 3 prior lines of treatment
• The result demonstrated a reduction in the risk of disease progression or death by 45%. At pre-planned interim analysis- median PFS is not yet reached- ORR (86.6% vs 82.9%)- CR (39.7% vs 27.6%)- VGPR rate (33% vs 28.5%)- OS were still immature
• The FDA marks the second approval for Sarclisa- also approved in combination with pomalidomide and dexamethasone (pom-dex) for the treatment of adults with RRM

  Ref: Sanofi | Image: Evaluate Pharma